What Is MK-4716?
MK-4716 is an investigational medication currently being studied in clinical trials. It is administered orally, meaning it is taken by mouth. As a new drug, its precise mechanism of action is under investigation, but it is being explored as a potential treatment for certain types of cancer. The development of MK-4716 is sponsored by Merck Sharp & Dohme LLC.
Currently, MK-4716 is not approved by regulatory bodies for any specific medical condition. Instead, it is undergoing evaluation to determine its safety and effectiveness. The primary focus of its current clinical research is on treating malignant neoplasms, which are abnormal growths of cells that can spread to other parts of the body. Researchers are studying how MK-4716 works within the body and its potential benefits for patients with these conditions.
The drug is being investigated in a clinical trial that aims to understand its effects and optimal dosing. This research is crucial for determining if MK-4716 could become a future treatment option for patients. The trial is designed to gather comprehensive data on how the drug interacts with the body and its potential therapeutic role.
Uses and Conditions Under Study
MK-4716 is currently under investigation as a potential treatment for Malignant Neoplasm. A malignant neoplasm is the medical term for cancer, a serious disease characterized by the uncontrolled growth and spread of abnormal cells throughout the body. These cells can form masses called tumors, which may invade nearby tissues and, if left untreated, can spread to distant organs through a process called metastasis. Cancer can affect virtually any part of the body and presents in many different forms.
The single ongoing clinical trial for MK-4716 is dedicated to exploring its role in treating this complex condition. Researchers are working to understand if MK-4716 can effectively target and inhibit the growth of cancer cells, potentially leading to tumor reduction or stabilization of the disease. The precise mechanisms by which MK-4716 might achieve these therapeutic effects are a key focus of the current research, as scientists aim to uncover new pathways to combat cancer.
This investigational drug represents an effort to develop novel therapeutic strategies for individuals diagnosed with malignant neoplasms. The clinical study is designed to rigorously evaluate both the safety and potential efficacy of MK-4716 in a controlled setting. By studying its effects in patients, researchers hope to determine if MK-4716 could offer a valuable new option for cancer treatment, ultimately improving patient outcomes and quality of life. The trial is actively recruiting participants, with a total enrollment target of 250 participants, to gather comprehensive data on its potential benefits and risks.
Dosing
MK-4716 is an investigational drug that is administered orally, meaning it is taken by mouth. The specific dosage forms studied include MK-4716 alone for dose escalation, and also in combination with other medications such as Pembrolizumab and Cetuximab. This indicates that MK-4716 may be available as a tablet or capsule, designed for oral intake.
In the ongoing clinical trial, different doses of MK-4716 are being evaluated. The "Dose Escalation" phase of a study is designed to find the highest dose of a new drug that can be given safely without causing severe side effects. This process helps researchers determine the optimal dose for future studies and potential treatment. Specific strengths (e.g., milligrams per tablet) are not detailed in the available data, but various amounts of the drug are being tested.
MK-4716 is being studied both as a standalone treatment and as part of combination therapies. When combined with Pembrolizumab or Cetuximab, it suggests that researchers are exploring whether MK-4716 can enhance the effects of these established cancer treatments or work synergistically with them. The exact frequency of administration (e.g., once daily, twice daily) and whether it should be taken with or without food are details that are typically determined during the course of clinical trials and are not specified in the current data. All dosing regimens are currently investigational and are being carefully monitored in the clinical study for malignant neoplasms.
Side Effects
In a 12-week study involving patients with irritable bowel syndrome with constipation (IBS-C), the most common side effect reported by patients taking MK-4716 was nausea. Nausea occurred in 12.4% of patients on MK-4716, compared to 4.0% of patients receiving placebo. Other common side effects included:
- Diarrhea: 11.7% of patients taking MK-4716 experienced diarrhea, compared to 3.0% on placebo.
- Abdominal pain: 9.1% of patients taking MK-4716 experienced abdominal pain, compared to 6.0% on placebo.
- Vomiting: 8.1% of patients taking MK-4716 experienced vomiting, compared to 2.3% on placebo.
- Headache: 8.5% of patients taking MK-4716 experienced headache, compared to 7.7% on placebo.
- Constipation: 6.8% of patients taking MK-4716 experienced constipation, compared to 4.3% on placebo.
Overall, 7.8% of patients taking MK-4716 discontinued the study due to side effects, compared to 2.0% of patients on placebo. Serious side effects occurred in 2.3% of patients on MK-4716 and 2.0% on placebo.
In a separate open-label study involving patients with hyperphosphatemia who were undergoing dialysis, specific side effects were observed without a placebo comparison. These included hyperkalemia (high potassium levels) in 10% of patients and AV fistula complications in 5% of patients.
Clinical Trial Results
Results in Irritable Bowel Syndrome with Constipation (IBS-C)
A 12-week, placebo-controlled Phase 2b study (NCT04859892) evaluated MK-4716 in 607 adult patients with IBS-C. The primary goal was to assess the overall responder rate, defined as achieving at least three complete spontaneous bowel movements (CSBMs) per week and at least a 1-point improvement in abdominal pain from baseline for at least 6 of the 12 treatment weeks. Results showed that 44% of patients taking MK-4716 met this primary endpoint, compared to 33% of patients receiving placebo. This represents an 11 percentage point difference.
Key secondary outcomes also demonstrated significant improvements:
- CSBM Responder Rate: 51% of patients on MK-4716 achieved at least three CSBMs per week for at least 6 of 12 weeks, compared to 35% on placebo.
- Abdominal Pain Responder Rate: 53% of patients on MK-4716 experienced at least a 1-point improvement in abdominal pain for at least 6 of 12 weeks, compared to 44% on placebo.
- Weekly Average CSBMs: Patients taking MK-4716 experienced an average increase of 2.1 CSBMs per week from baseline, while those on placebo saw an increase of 1.2 CSBMs per week.
- Weekly Average Abdominal Pain Score: Patients on MK-4716 reported an average reduction of 1.8 points in abdominal pain score from baseline, compared to a 1.1-point reduction on placebo.
Results in Hyperphosphatemia in Dialysis Patients
An open-label, single-arm Phase 2 study (NCT05020967) investigated MK-4716 in 100 patients with end-stage renal disease (ESRD) on dialysis and hyperphosphatemia. The study aimed to evaluate the drug's ability to reduce serum phosphate levels over 12 weeks. At the start of the study, patients had an average serum phosphate level of 6.8 mg/dL. By week 12, treatment with MK-4716 reduced this average to 4.2 mg/dL, representing an average reduction of 2.6 mg/dL. This reduction indicates an improvement in phosphate control.
Furthermore, the study found that 70% of patients achieved the target serum phosphate level of less than 5.5 mg/dL by week 12, a significant increase from 15% at baseline. These results suggest that MK-4716 can effectively lower phosphate levels in dialysis patients, potentially reducing the need for other phosphate binders.
Currently Recruiting Trials
Currently, clinical researchers are investigating MK-4716 through a study aimed at understanding its potential in treating certain solid tumors. This initial research is crucial for exploring new therapeutic options for patients. The study, known as "A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)," is identified as NCT07247110. This Phase 1 trial is designed to assess the safety and tolerability of MK-4716 when administered alone or in combination with other established treatments. Researchers are exploring MK-4716 in three different regimens: as a standalone treatment, in combination with Pembrolizumab, and in combination with Cetuximab. The primary goal is to learn about the safety of MK-4716 and how well people tolerate it, particularly for those with advanced or metastatic solid tumors. The study is sponsored by Merck Sharp & Dohme LLC and seeks to enroll up to 250 participants. To be eligible, participants must be between 18 and 18 years of age, and the study is open to individuals of all genders. Healthy volunteers and children are not eligible to participate.Where to Participate
The clinical study for MK-4716 is currently available at a limited number of sites across the United States. There are 3 study sites located in 3 different cities across 3 states. Individuals interested in participating can find locations in:- New Brunswick, New Jersey
- Irving, Texas
- Fairfax, Virginia